1. Home
  2. ANAB vs IRS Comparison

ANAB vs IRS Comparison

Compare ANAB & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$48.44

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

IRS

IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

HOLD

Current Price

$14.53

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
IRS
Founded
2005
1943
Country
United States
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2015
1998

Fundamental Metrics

Financial Performance
Metric
ANAB
IRS
Price
$48.44
$14.53
Analyst Decision
Strong Buy
Buy
Analyst Count
8
3
Target Price
★ $87.25
$21.87
AVG Volume (30 Days)
★ 510.1K
172.6K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
★ 9.82%
EPS Growth
★ 91.02
N/A
EPS
N/A
★ N/A
Revenue
★ $234,603,000.00
N/A
Revenue This Year
$17.97
N/A
Revenue Next Year
$36.88
$7.14
P/E Ratio
★ N/A
$3.66
Revenue Growth
★ 157.01
N/A
52 Week Low
$30.27
$13.11
52 Week High
$73.30
$19.14

Technical Indicators

Market Signals
Indicator
ANAB
IRS
Relative Strength Index (RSI) 48.05 53.94
Support Level $44.43 $14.50
Resistance Level $51.27 $14.61
Average True Range (ATR) 2.29 0.43
MACD 0.44 0.09
Stochastic Oscillator 58.84 95.77

Price Performance

Historical Comparison
ANAB
IRS

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.

Share on Social Networks: